Peter Rahmer Sells 1,354 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 1,354 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $11,441.30. Following the completion of the transaction, the insider owned 276,610 shares of the company’s stock, valued at approximately $2,337,354.50. This represents a 0.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, January 27th, Peter Rahmer sold 11,684 shares of Relay Therapeutics stock. The stock was sold at an average price of $7.62, for a total transaction of $89,032.08.

Relay Therapeutics Price Performance

NASDAQ RLAY opened at $7.66 on Friday. The stock has a market capitalization of $1.33 billion, a PE ratio of -4.38 and a beta of 1.55. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.04. The company’s 50 day simple moving average is $7.97 and its two-hundred day simple moving average is $5.97.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). On average, research analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Institutional Investors Weigh In On Relay Therapeutics

A number of large investors have recently modified their holdings of the stock. Commodore Capital LP lifted its holdings in Relay Therapeutics by 27.3% in the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after buying an additional 3,650,000 shares during the period. Vanguard Group Inc. raised its position in shares of Relay Therapeutics by 3.1% in the 4th quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after acquiring an additional 295,701 shares in the last quarter. Bellevue Group AG boosted its position in shares of Relay Therapeutics by 1.4% during the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after purchasing an additional 114,740 shares in the last quarter. Geode Capital Management LLC grew its stake in Relay Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock worth $11,176,000 after purchasing an additional 159,548 shares during the period. Finally, Millennium Management LLC raised its holdings in Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on RLAY. Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $6.00 to $13.00 in a research report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective for the company in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Key Relay Therapeutics News

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.